Furthermore, the deduction of MDSCs by the combination therapy increased CD3+, CD4+, and CD8+ T cell infiltration to tumor tissues more than anti-PD-L1 single therapy (Figures 5(j) and 5(k)). The gene discussed is CD8A; the disease is neoplasm.